Is Rivaroxaban Noninferior to Standard Warfarin Therapy in Preventing Recurrent PE and DVT?

Because the initial determination of who had PE or DVT occurred before submitting the patient's information for blind adjudication, patient and researcher perceptions could have been affected, leading to bias in referral for adjudication (see the study's supplemental protocol at http://www.nejm.org/doi/full/10.1056/NEJMoa1113572). Bob: As you can see, the researcher has a great amount of control over whether a drug will be called noninferior. Because of potential researcher bias in defining “clinically significantly inferior,” and thus the noninferiority margin, a useful starting point is often the lower limit of efficacy of the standard drug as determined in the literature. [...]there was no difference in prolonged hospitalizations, need to discontinue the drug, any serious events, and any emergent event.